In this study, a prospective study is used to select patients who will undergo intra-abdominal endoscopic single-port surgery system for benign gynecological diseases from February 2025 to December 2026 in the Second Affiliated Hospital of Wenzhou Medical University, including hysterectomy, myomectomy, ovarian cyst removal and adnexectomy. The study will perform statistical analysis to evaluate the feasibility and the main factors affecting the safety of intra-abdominal endoscopic single-port surgery system(SR-ENS-600) used in gynecological day surgery.

Start Date10 Apr 2025

Sponsor / Collaborator

Second Affiliated Hospital of Wenzhou Medical University

NCT06890143

/ Not yet recruitingPhase 3IIT

The Efficacy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disease With Proteinuria in Children: a Prospective, Randomized Crossover Trial

This study is a multicenter, randomized controlled crossover trial aimed to evaluate the efficacy and safety of dapagliflozin in the treatment of hereditary kidney disease with proteinuria in children

Start Date21 Mar 2025

Sponsor / Collaborator

Paediatrics Hospital Affiliated To Fudan University

[+8]

NCT06955143

/ RecruitingNot ApplicableIIT

A Study on Integrated Multi-Omics and Multi-Factor Analysis of Peripheral Blood in Patients With Acute Coronary Syndrome

The goal of this study is to conduct analyses the changes of cell growth factors, inflammatory factors, metabolites, plasma proteome, etc. in the blood of patients with ACS (acute coronary syndrome), as well as their correlations with the disease prognosis, based on multi-omics or other related research methods. The main questions it aims to answer are:
The growth factors that have significant changes in the peripheral blood of the ACS population, especially fibroblast growth factors? Inflammatory factors and chemokines related to the onset of ACS? The metabolites and proteins that are significantly altered in the peripheral blood after the onset of ACS? Researchers will compare ACS population to control group (patients without coronary artery stenosis, valvular heart disease, structural heart disease, or any other kind of cardiomyopathy).
The peripheral venous blood from the participants will be collected within 24 hours after their admission to the hospital.

Start Date11 Mar 2025

Sponsor / Collaborator

Second Affiliated Hospital of Wenzhou Medical University

[+1]

100 Clinical Results associated with Second Affiliated Hospital of Wenzhou Medical University

0 Patents (Medical) associated with Second Affiliated Hospital of Wenzhou Medical University

217

Literatures (Medical) associated with Second Affiliated Hospital of Wenzhou Medical University

01 Oct 2025·Biomaterials

Overcoming radiation-induced PD-L1 and COX-2 upregulation by nitric oxide gas nanogenerator to sensitize radiotherapy of lung cancer

Article

Author: Zhou, Zaigang ; Lyu, Yuehua ; Zhu, Lijie ; Zhao, Zhenzhou ; Huang, Ruoyuan ; Sun, Wenjie ; Hu, Rui ; Shi, Mengke ; Meng, Rui ; Xie, Congying ; Yang, Rongbo ; Xue, Fei ; Jiang, Xin ; Shen, Jianliang

Currently, certain lung cancer patients exhibit resistance to radiotherapy due to reduced DNA damage under hypoxic conditions and the cytoprotective and immune-resistance effect caused by increased programmed death ligand-1 (PD-L1) and Cyclooxygenase 2 (COX-2) expression after radiotherapy. At present, existing nanoparticles or drugs could hardly effectively, and easily address these obstacles faced by highly effective radiotherapy simultaneously, especially the simultaneous depression of PD-L1 and COX-2. In this study, it is newly proved that some typical nitric oxide (NO) gas donors could co-inhibit PD-L1 and COX-2 expression, revealing the possible not fully proven role of NO in reversing tumor immunotherapy resistance. Then, to realize selective NO generation in tumors, a simple tumor glutathione (GSH) responsive NO gas nanogenerator named SAB-NO nanoparticles was designed and prepared, which was composed of the NO donor Isoamyl Nitrite conjugated with serum albumin (SAB). By doing this, SAB-NO nanoparticles more effectively sensitized radiotherapy through breaking the cytoprotective effects faced by radiotherapy in vitro by generating more DNA damage through reversing tumor hypoxia and impairing the DNA damage repair process through decreasing PD-L1 expression. Then, the combination therapy of SAB-NO nanoparticles and radiotherapy effectively transformed cold tumors into hot ones through avoiding some potential immune-resistance effects induced by radiotherapy treatment alone through PD-L1 and COX-2 co-inhibition. In conclusion, the combined treatment of radiotherapy and SAB-NO nanoparticles finally almost completely suppressed the growth of lung tumors, revealing the novel role of NO donors in sensitizing tumor immunotherapy by avoiding the potential cytoprotective and immune-resistance effects.

01 Jun 2025·Nano Today

Selenium nanoparticles restrain recurrence of cervical cancer in drug-free period by inhibiting the expression of ABC transporters

Author: Liu, Hejing ; Chen, Tianfeng ; Zhang, Zihan ; Lan, Jingyuan ; Yang, Ziyi ; Pan, Shuya ; Liu, Ting ; Zhu, Xueqiong ; He, Lizhen ; Hua, Ying ; Zhou, Qingfeng

Cervical cancer remains the one of the most frequent malignant tumors in women around the world.Cisplatin-based chemotherapy is a prevalent treatment for advanced cervical cancer, but it has significant side effects that necessitate drug-free periods during treatment cycles.Unfortunately, tumors often relapse during these intervals, highlighting the need for strategies to prevent recurrence.In the present study, the biol. changes in cervical cancer cells following the withdrawal of cisplatin chemotherapy were investigated.Afterwards, the application of selenium nanoparticles (SeNPs) modified with lentinan (LNT) to address tumor recurrence during these drug-free periods was explored.Specifically, in vitro experiments demonstrated that SeNPs@LNT effectively inhibited tumor recurrence by promoting DNA damage, inducing apoptosis, and disrupting mitochondrial membrane potential.Addnl., in vivo experiments showed that SeNPs@LNT had a strong antitumor effect on cervical cancer during the drug-free period.It also remarkable that SeNPs@LNT might prevent the development of drug resistance by suppressing the expression of the ABC transporter and VEGF.Our findings suggest that SeNPs@LNT is a promising candidate for maintaining chemotherapy efficacy during the drug-free intervals of cisplatin treatment.

01 Jun 2025·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease

The IGF2BP2-circ-DAPK1 axis promotes high-glucose-induced ferroptosis of HUVECs by decreasing NQO1 expression

Article

Author: Xu, Yiting ; Qiu, Chenyang ; Wang, Bing ; Chen, Tianchi ; Wu, Ziheng ; Zheng, Xiangtao ; Lu, Wei ; Zhou, Xiaoxiang ; Yu, Xinyu

Circular RNAs (circRNAs) are non-coding RNAs with covalently closed loop structures that participate in various biological processes. However, the functions of many circRNAs remain unclear. Endothelial cell dysfunction, which involves abnormal ferroptosis, a unique form of regulated cell death, is a characteristic of various diseases. However, the mechanisms governing ferroptosis in endothelial cells are not fully understood. Here, we investigated the impact of a novel circRNA, circ-DAPK1, on ferroptosis in human umbilical vein endothelial cells (HUVECs) under high-glucose conditions. Our data showed that high-glucose conditions upregulate circ-DAPK1 expression in HUVECs. Overexpression of circ-DAPK1 induced ferroptosis in HUVECs, whereas depletion of circ-DAPK1 mitigated the ferroptosis triggered by high-glucose treatment. Inhibition of ferroptosis reversed the decrease in cell viability induced by high glucose or circ-DAPK1 overexpression. Using RNA immunoprecipitation analyses, we identified several ferroptosis-regulating proteins, including NAD(P)H dehydrogenase [quinone] 1 (NQO1) and insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2). Mechanistically, circ-DAPK1 interacts with NQO1, enhancing its ubiquitination and accelerating its degradation. NQO1 overexpression partially rescues HUVECs from high-glucose-induced ferroptosis. We also found that IGF2BP2 binds to the m⁶A site on circ-DAPK1. Depletion of IGF2BP2 in HUVECs reduced circ-DAPK1 expression and inhibited high-glucose-induced ferroptosis. These findings reveal the effects of the IGF2BP2-circ-DAPK1 axis in regulating ferroptosis in HUVECs under high-glucose conditions and extend our understanding of the mechanisms controlling ferroptosis in endothelial cells.

100 Deals associated with Second Affiliated Hospital of Wenzhou Medical University

100 Translational Medicine associated with Second Affiliated Hospital of Wenzhou Medical University

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 13 Aug 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Preclinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

NL13 ( PLK4 )	Prostatic Cancer More	Preclinical
GSK-3179106 ( RET x p38 MAPK )	Inflammation More	Preclinical
CN115634212 ( CXCRs )	Neoplasms More	Discovery

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis